IP Library Granted Patent US 6,852,707
Granted Patent B1
US 6,852,707 · App. 09/857,695 · Granted Feb 8, 2005

Remedies for hyperammonemia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,852,707
App. No.
09/857,695
Granted
Feb 8, 2005
Kind
B1
Abstract

By using xylobiose or xylooligosaccharide containing xylobiose as a main ingredient in place of lactulose, there is provided a blood ammonia lowering agent, a therapeutic agent of hyperammonemia or a therapeutic agent of hepatic encephalopathy that need be adminstered in smaller doses and which have no concern over side effects. Lactulose conventionally used as such drugs has to be administered in high doses and involves a safety problem when administered to patients with galactosemia or diabetes mellitus. The drug of the invention which contains xylobiose as a main ingredient solves these problems.

Claims (6)

1. A blood ammonia lowering agent containing xylooligosaccharide containing at least 30 wt % to less than 45 wt % of xylobiose, as an active ingredient.

2. The blood ammonia lowering agent according to claim 1 , which comprises said xylobiose or said xylooligosaccharide and a pharmaceutically acceptable carrier.

3. A therapeutic agent of hyperammonemia containing xylooligosaccharide containing at least 30 wt % to less than 45 wt % of xylobiose, as an active ingredient.

4. The therapeutic agent of hyperammonemia according to claim 3 , which comprises said xylobiose or said xylooligosaccharide and a pharmaceutically acceptable carrier, wherein said therapeutic agent has the activity of promoting the growth of organic acid producing enterobacteria.

5. A therapeutic agent of hepatic encephalopathy containing xylooligosaccharide containing at least 30 wt % to less than 45 wt % of xylobiose, as an active ingredient, wherein said therapeutic agent has the activity of promoting the growth of organic acid producing enterobacteria.

6. The therapeutic agent of hepatic encephalopathy according to claim 5 , which comprises said xylobiose or said xylooligosaccharide and a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2009
From: SUNTORY LTD.
To: SUNTORY HOLDINGS LTD.
Reel/Frame 022610/0105 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2001
From: KISO, YOSHINOBU; IINO, TAEKO; KATO, SHINZO
To: SUNTORY LIMITED
Reel/Frame 011971/0802 →